Real clinical experience from PAH Experts

See why these pulmonary specialists start with Adempas

Adempas is approved for adults with PAH (WHO Group 1) and has been studied predominantly in WHO Functional Class II–III patients.

In one-on-one interviews with pulmonary hypertension (PH) specialists, we hear their insights on treating patients with pulmonary arterial hypertension (PAH) (WHO Group 1) and discuss their clinical experience with Adempas.

Learn more about how these healthcare professionals assess treatment strategies for their PAH patients, and why they start with Adempas.

Expert insights

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Hunter Champion, MD, PhD, FAHA*

Pulmonary Hypertension and Heart Failure

See why Dr. Champion’s goal is getting a patient to low risk status

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


J Wesley McConnell, MD*

Critical Care Medicine, Interventional Pulmonology

Find out why Dr. McConnell thinks early treatment can really make a difference

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Therese Sargent, NP*

Nurse Practitioner Specialist, Pulmonary Hypertension

Learn why Ms. Sargent thinks diagnosing patients earlier is important

*Compensated by Bayer for interview.

 
MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION